Kiniksa Pharmaceuticals International (KNSA) Change in Receivables (2021 - 2026)

Kiniksa Pharmaceuticals International's Change in Receivables history runs 6 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• Quarterly Change in Receivables rose 559.92% year-over-year to $7.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.8 million (down 169.97% YoY) and the FY2025 annual result came in at -$26.1 million, down 227.73% from the prior year.
• Change in Receivables was $7.6 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from -$36.1 million in the prior quarter.
• Across five years, Change in Receivables topped out at $25.5 million in Q1 2022 and bottomed at -$36.1 million in Q4 2025.
• A 5-year average of $1.1 million and a median of $3.4 million in 2022 frame the typical range for Change in Receivables.
• Peak annual rise in Change in Receivables reached 1114.19% in 2023, while the deepest fall reached 744.85% in 2023.
• Kiniksa Pharmaceuticals International's Change in Receivables stood at $1.5 million in 2022, then soared by 1114.19% to $18.2 million in 2023, then retreated by 7.62% to $16.8 million in 2024, then slumped by 314.71% to -$36.1 million in 2025, then jumped by 121.11% to $7.6 million in 2026.
• Business Quant data shows KNSA's Change in Receivables at $7.6 million in Q1 2026, -$36.1 million in Q4 2025, and $19.8 million in Q3 2025.